Madrigal says MAESTRO-NASH analysis shows Rezdiffra efficacy consistent across MASH genetic risk variants

Bitget2026/10/06 12:06

Madrigal Pharmaceuticals reported new Journal of Hepatology data from a secondary analysis of its Phase 3 MAESTRO-NASH trial. Results were presented as a publication, not flagged for a future conference release. Rezdiffra showed broadly consistent benefits on liver disease measures across common genetic risk variants tied to MASH progression. Findings support use across genetically diverse patients, reducing the need to segment treatment by genotype in near-term commercialization. Analysis covered 738 trial participants with genetic testing and paired biopsies, limiting conclusions on rarer variants or small subgroup effects. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840426) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

TD Cowen lowers UnitedHealth target price to $402

格隆汇•2026/10/10 09:31

Specter questions the issuance and refund arrangements of Serpin token

AiCoin•2026/10/10 09:29

BMO raises target price for cybersecurity stocks

格隆汇•2026/10/10 09:19

Needham raises CrowdStrike target price to $310

格隆汇•2026/10/10 08:39